Tumor-targeted immunotherapy is a remarkable breakthrough,offering the inimitable advantage of specific tumoricidal effects with reduced immune-associated cytotoxicity.However,existing platforms suffer from low effica...Tumor-targeted immunotherapy is a remarkable breakthrough,offering the inimitable advantage of specific tumoricidal effects with reduced immune-associated cytotoxicity.However,existing platforms suffer from low efficacy,inability to induce strong immunogenic cell death(ICD),and restrained capacity of transforming immune-deserted tumors into immune-cultivated ones.Here,an innovative platform,perfluorooctyl bromide(PFOB)nanoemulsions holding MnO_(2) nanoparticles(MBP),was developed to orchestrate cancer immunotherapy,serving as a theranostic nanoagent for MRI/CT dual-modality imaging and advanced ICD.By simultaneously depleting the GSH and eliciting the ICD effect via highintensity focused ultrasound(HIFU)therapy,the MBP nanomedicine can regulate the tumor immune microenvironment by inducing maturation of dendritic cells(DCs)and facilitating the activation of CD8^(+)and CD4^(+)T cells.The synergistic GSH depletion and HIFU ablation also amplify the inhibition of tumor growth and lung metastasis.Together,these findings inaugurate a new strategy of tumor-targeted immunotherapy,realizing a novel therapeutics paradigm with great clinical significance.展开更多
In the USA,there were about 1806590 new cancer cases in 2020,and 606520 cancer deaths are expected to have occurred in 2021.Lung cancer has become the leading cause of death from cancer in both men and women(Siegel et...In the USA,there were about 1806590 new cancer cases in 2020,and 606520 cancer deaths are expected to have occurred in 2021.Lung cancer has become the leading cause of death from cancer in both men and women(Siegel et al.,2020).Clinical studies show that the five-year survival rate of lung cancer patients after early diagnosis and treatment intervention can reach 80%,compared with that of patients having advanced lung cancer.Thus,the early diagnosis of lung cancer is a key factorto reduce mortality.展开更多
基金supported by Shanghai Municipal Science and Technology Major Project(No.2018SHZDZX01,China)ZJ Lab,Shanghai Natural Science Foundation(Grant No.18ZR1405700,China)+3 种基金National Natural Science Foundation of China(Fund Nos.81773283 and 81901697)Shanghai Sailing Program(Grant No.18YF1403000,China)Shanghai Chest Hospital Project of Collaborative Innovation(Grant No.YJXT20190203,China)the Opening Project of State Key Laboratory of High Performance Ceramics and Superfine Microstructure(SKL201908SIC,China)。
文摘Tumor-targeted immunotherapy is a remarkable breakthrough,offering the inimitable advantage of specific tumoricidal effects with reduced immune-associated cytotoxicity.However,existing platforms suffer from low efficacy,inability to induce strong immunogenic cell death(ICD),and restrained capacity of transforming immune-deserted tumors into immune-cultivated ones.Here,an innovative platform,perfluorooctyl bromide(PFOB)nanoemulsions holding MnO_(2) nanoparticles(MBP),was developed to orchestrate cancer immunotherapy,serving as a theranostic nanoagent for MRI/CT dual-modality imaging and advanced ICD.By simultaneously depleting the GSH and eliciting the ICD effect via highintensity focused ultrasound(HIFU)therapy,the MBP nanomedicine can regulate the tumor immune microenvironment by inducing maturation of dendritic cells(DCs)and facilitating the activation of CD8^(+)and CD4^(+)T cells.The synergistic GSH depletion and HIFU ablation also amplify the inhibition of tumor growth and lung metastasis.Together,these findings inaugurate a new strategy of tumor-targeted immunotherapy,realizing a novel therapeutics paradigm with great clinical significance.
基金the National Natural Science Foundation of China(No.81830052)the Science and Technology Innovation Action Plan of Shanghai(No.18441900500)the Shanghai Natural Science Foundation of China(No.20ZR1438300)。
文摘In the USA,there were about 1806590 new cancer cases in 2020,and 606520 cancer deaths are expected to have occurred in 2021.Lung cancer has become the leading cause of death from cancer in both men and women(Siegel et al.,2020).Clinical studies show that the five-year survival rate of lung cancer patients after early diagnosis and treatment intervention can reach 80%,compared with that of patients having advanced lung cancer.Thus,the early diagnosis of lung cancer is a key factorto reduce mortality.
